These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18414397)

  • 1. Discovery and biological characterization of a novel series of androgen receptor modulators.
    Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
    Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
    Cherian MT; Wilson EM; Shapiro DJ
    J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circumventing anti-androgen resistance by molecular design.
    McGinley PL; Koh JT
    J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
    Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
    Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
    Segal CV; Koufaris C; Powell C; Gooderham NJ
    Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
    Hamann LG; Higuchi RI; Zhi L; Edwards JP; Wang XN; Marschke KB; Kong JW; Farmer LJ; Jones TK
    J Med Chem; 1998 Feb; 41(4):623-39. PubMed ID: 9484511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists.
    Ng RA; Guan J; Alford VC; Lanter JC; Allan GF; Sbriscia T; Lundeen SG; Sui Z
    Bioorg Med Chem Lett; 2007 Feb; 17(4):955-8. PubMed ID: 17134895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile.
    Hikichi Y; Yamaoka M; Kusaka M; Hara T
    Eur J Pharmacol; 2015 Oct; 765():322-31. PubMed ID: 26335395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
    Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
    Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
    J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
    Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
    Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
    Salvati ME; Balog A; Shan W; Rampulla R; Giese S; Mitt T; Furch JA; Vite GD; Attar RM; Jure-Kunkel M; Geng J; Rizzo CA; Gottardis MM; Krystek SR; Gougoutas J; Galella MA; Obermeier M; Fura A; Chandrasena G
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1910-5. PubMed ID: 18291644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.